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1. Introduction
Osteoporosis is a metabolic bone disease known as “the silent thief” because the gradual loss
of bone associated with this disease usually occurs over the years, and there are usually no
noticeable symptoms until the bones are so fragile that a fracture occurs [1]. Although most
statistics on the prevalence of osteoporosis quoted in the literature are from those published
in 1991 to 2004 [2,3] the projection is nevertheless very consistent. Thus, osteoporosis is
estimated to affect over 200 million people worldwide and 75 million people in Europe, the
United States, and Japan [4]. Approximately 1 in 2 women and 1 in 5 men older than 50 years
will eventually experience osteoporotic fractures [5] An increase in the worldwide incidence
of hip fracture by 240% in women and 310% in men is projected by the year 2050 [6]. Osteo‐
porosis is “a major public health threat” that is projected to results to 8.1 million fractures (78
% women, 22 % men) during the period between 2010 and 2050 [7]. The condition costs our
healthcare system $18 billion per year [8]. Records show that Osteoporosis has been known to
exist since the Egyptian mummies have been found with suspected dowager’s hump [9].
Newer findings on all aspects of osteoporosis have increased exponentially. The more
importantly ones are the introduction and improvement in more sensitive diagnostic instru‐
ments, discovering an ever increasing number of risk factors including oxidative stress,
opening up new knowledge on the involvement of the bone forming cells osteoblasts and the
bone resorbing cells osteoclasts in the development of osteoporosis and finding new drugs
and the nutritional alternatives for the prevention and treatment of osteoporosis. Advances in
knowledge on osteoporosis is not without pitfalls. Hormone Replacement Therapy (HRT),
once a first line of treatment for osteoporosis has been discontinued due to side effects [10]. It
is becoming more evident that the drugs known as bisphosphonates, although effective in
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stopping the resoption of bone and preventing osteoporosis in women, are associated with a
number of side effects [11,12]. The side effects have been alarming a number of women with
osteoporosis in such a way that they are now resorting to other mode of treatment, including
that from natural food components. Our laboratory has carried out studies on the use of
antioxidants such as lycopene and polyphenols as possible alternatives and/or complementa‐
ries to drugs in the treatment and prevention of osteoporosis. This chapter will include an
overview on osteoporosis, the role of oxidative stress in bone cells osteoclasts and osteoblasts,
oxidative stress as a risk factor in the development of osteoporosis and a review of studies on
the use of antioxidants in counteracting oxidative stress in the prevention of osteoporosis.
These topics should put our research in perspective and offer a rationale to our study ap‐
proaches. Finally we will highlight our pioneering studies on the effects of the lipid-soluble
antioxidant lycopene and the water-soluble antioxidant polyphenols present in a nutritional
supplement in an in vitro cultures of osteoblasts and osteoclasts and our clinical studies in the
prevention of risk for osteoporosis in postmenopausal women.
2. Osteoporosis — Overview
2.1. Bone cells involved in the development of osteoporosis
Bone as a dynamic tissue continuously renews itself throughout life by the process of bone
remodeling carried out by a functional and anatomic structure known as the basic multicellular
unit (BMU) that requires the coordinated action of three major types of bone cells: osteoclasts,
osteoblasts and osteocytes [13,14]. The remodeling process is the result of interactions between
these cells and multiple molecular agents, including hormones, growth factors, and cytokines.
Bone remodeling is a physiological process that follows a time sequence lasting approximately
six months wherein osteoclasts eliminate old or damaged bone which is subsequently replaced
with new bone formed by osteoblasts, while the osteocytes functions in the transduction of
signals necessary to sustain mechanical loads. The coupled process of bone formation and bone
resorption in mature, healthy bone is tightly regulated and maintained in order to prevent a
significant alterations in bone mass or mechanical strength after each remodeling cycle [14,15].
At menopause when estrogen production is decreased, the increase in resorption cavities due
to increased bone resorption, but insufficient increase in bone formation, results to incomplete
filling of resorption cavities with new bone leading to a permanent loss of bone mass. Distur‐
bances in the remodeling process of this nature can lead to metabolic bone diseases. One such
disturbance caused by oxidative stress, shown to control the functions of both osteoclasts and
osteoblasts, may contribute to the pathogenesis of skeletal system including osteoporosis, the
most prevalent metabolic bone disease [16].
2.2. Prevalence of osteoporosis
Women over the age of 50 become susceptible to osteoporosis because of the loss of estrogen
at menopause [17]. As well, men’s susceptibility to osteoporosis is due to low levels of the sex
hormone testosterone [18-20]. In the past, a majority of men view osteoporosis as solely a
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“woman’s disease.” This is because men in their fifties do not experience the rapid loss of bone
mass that women do in the years following menopause, and therefore men osteoporosis does
not set in until later in life [21,22]. However, by age 65 to 70, men and women are losing bone
mass at the same rate [23]. The World Health Organization (WHO) aptly defined osteoporosis
as a systemic disease that is characterized by low bone mass and deterioration of the micro‐
architecture of bone, resulting in an increased risk of fracture. Bone mass or bone mineral
density (BMD) is measured using a dual-energy x-ray absorptiometry, or DXA, at various
skeletal sites, including the spine, hip and wrist [24].
2.3. Bone mineral density as predictor of osteoporosis
BMD is expressed as T-score which is a value compared to the expected value for young adults
of the same sex and race. WHO has established that for normal BMD, the T-score is between
standard deviation of +2.5 and -1.0; for osteopenia/low BMD, T-score is between -1.0 and -2.5,
inclusive; for osteoporosis, T-score is lower than -2.5 and for severe osteoporosis,T-score is
lower than -2.5 with the presence of one or more fragility fractures [25]. Thus BMD values can
identify osteoporosis, determine the risk for fractures (broken bones), and measure the
response to osteoporosis treatment [26]. In the case of severe osteoporosis, minimal trauma
such as a minor fall or just a hug from a loved one can result to fragility fracture. Fragility
fracture is defined by WHO as “a fracture caused by injury that would be insufficient to cause
fracture normally. The spine, hip and distal forearm are the most common sites of fragility
fracture [27]. Some doctors recommend that people be tested on a regular basis for bone loss.
For women, those tests should begin after menopause. For men, they should begin after the
age of sixty-five. Such tests are important since there are seldom other signs of osteoporosis.
Therefore, those who have a higher rate of bone loss and are at higher risk for a fracture need
a better diagnostic tool. Recently, the WHO introduced a prognostic tool to evaluate fracture
risk of patients called the FRAX® [28]. The FRAX tool takes into account country, bone mineral
density of the hip (when available), age, sex, and 8 clinical risk factors to calculate the 10-year
probability of a major osteoporotic fracture and the 10-year probability of a hip fracture [29].
It assesses the 10-year risk of osteoporosis based on individual patient models that combines
clinical risk factors (CRF) as well as BMD at the femoral neck [30].
2.4. Bone turnover markers for detecting osteoporosis
During bone remodeling in healthy young adult, bone formation by osteoblasts equals bone
resorption by osteoclasts. However In postmenopausal bone loss, the remodeling process
becomes significantly more active with a primary increase in bone resorption and a corre‐
sponding, but an insufficient increase in bone formation [31]. Enzymes and/or other proteins
are released into the blood that are considered to reflect either bone formation or bone
resorption [32] and are termed as bone turnover markers. Molecular markers of bone turnover
have been developed as a product of bone remodeling [31] in the diagnostic and therapeutic
assessment of metabolic bone disease [33]. They are now used for the individual monitoring
of osteoporotic patients treated with antiresorptive agents [34]. Specific and sensitive assess‐
ment of the rate of bone formation and bone resorption and prediction of fracture [35] can now
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be possible using commercially available biochemical markers [36]. It remained to be seen
whether bone turnover markers might contribute a useful independent risk factor for inclusion
in FRAX [30]. The bone turnover markers we used for our clinical studies were crosslinked N-
telopeptide of type I collagen (NTx) [37-39] and crosslinked C-telopeptide of type I collagen
(CTx) [40,41] as bone resorption markers and bone alkaline phosphatase (BAP) [37-39] and
Procollagen type I N-terminal propeptide (PINP) [40,41] for a measure of bone formation in
the serum of participants.
Although BMD is considered the best parameter for determining the osteoporotic status of
men and women, BMD is static and cannot predict changes that may occur post-measurement
[42]. As well, changes in BMD occur slowly and can take up to one to two years to be detected
during the course of therapy [43,44]. An alternative or additional parameters now measured
clinically as either formation or resorption markers in the urine or serum of participants are
bone turnover markers which can reveal changes much earlier in the course of therapy
compared to changes in BMD [34]. When combined with BMD measurement, changes in bone
turnover markers have been significantly linked to fracture risk due to a significant positive
correlation between high bone turnover markers and loss of BMD [35]. Bone turnover markers
are therefore very useful in assessing treatment protocol for a short duration period, e.g., 3 to
6 months. Measurement of bone turnover markers was therefore utilized in our clinical study
during which postmenopausal women were given the antioxidant lycopene for 3 months
[37-39] and in another study during which nutritional supplement greens+bone builderTM were
administered for a period of eight weeks [40,41]. As will be reviewed in later sections, during
the short period of treatment, positive changes were measured that correlated decreased bone
resorption markers with decreases in oxidative stress parameters and thereby to decrease of
risk for osteoporosis in postmenopausal women.
2.5. Risk factors of osteoporosis
Some of the risk factors for osteoporosis [45,46] are presented in Table 1 [47]. The risk factors
that are of interest in our studies are oxidative stress-generating factors, including smoking,
alcohol intake, low antioxidant status, nutrition deficiency, excessive sports activity and
excessive caffeine intake. Oxidative stress will be reviewed in detail below.
2.6. Prevention and treatment of osteoporosis
Up until 10 years ago, the first line of treatment for women who have gone through menopause
and was diagnosed with osteoporosis was hormone replacement therapy (HRT). However, re‐
sults of the Women’s Health Initiative (WHI) warned women that HRT leads to higher risks for
breast cancer, cardiovascular events, blood clots, cognitive decline, and more [10]. This treat‐
ment for osteoporosis has since been discontinued and is prescribed only for a short period of
time to alleviate hot flashes in menopausal women [48]. A wide range of pharmaceuticals are
available for the treatment of osteoporosis. The current antiresorptive treatments approved by
the Food and Drug Administration (FDA) include a number of bisphosphonates under specific
trademarks which inhibit bone resorption [49]. Some are taken daily while others are formulat‐
ed for weekly, monthly or intermittent oral use [50,51]. The newer bisphophonates are injecta‐
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bles  such as  ibandronate  and Zoledronate  [51]  Other  drugs available  include calcitonin,
strontium renalate and the Selective Estrogen Receptor Modulator (SERM), Raloxifene (Evista)
[52]. Parathyroid hormone, PTH1-34 or teriparatide (Forteo), is the only anabolic agent current‐
ly approved for use by the FDA [24,53]. The new class of osteoporosis medications now ap‐
proved for use is a fully human monoclonal antibody (Denosumab) which bind to RANKL,
imitating the effects of OPG and acting as an inhibitor of RANKL [54]. A number of other drugs
are being tested clinically for osteoporotic treatment and prevention.[24].
Unmodifiable Modifiable
Race
Sex
Age
Genetics
Body size
Family History
Previous Fractures
Chronic inactivity
Low body weight
Low lifetime calcium intake
Medication used
Oxidative stress-related factors
Smoking
Alcohol intake
Low antioxidant status
Nutrition deficiency
Excessive sports activity
Excessive caffeine intake
Table 1. Risk Factors for Osteoporosis
None of the drugs are without side effects. Side effects that emerged in clinical trials include
esophageal irritation with oral administration and acute phase response with iv treatment or
high-dose oral therapy. Uncommon side effects that have been noted with wide clinical use in‐
clude osteonecrosis of the jaw, musculoskeletal complaints, and atypical fractures. The num‐
bers of events are small, and a clear cause-and-effect relationship between these events and
bisphosphonate treatment has not been established. Because Bisphosphonates accumulate in
the bone, they create a reservoir leading to continued release from bone for months or years and
provide some residual antifracture reduction when treatment is stopped. For this reason, there
is a recommendation for a drug holiday after 5 –10 yr of bisphosphonate treatment [12,55]. The
length of the holiday is based on fracture risk and previous duration of treatment and BMD sta‐
tus. Studies with risedronate and alendronate suggest that if treatment is stopped after 3–5 yr,
there is persisting antifracture efficacy, at least for 1–2 yr. For those who are not on holiday, the
consensus from expert panels [12] suggest not stopping the use of drug since the side effects are
often rare, and that the benefits outweigh the side effects. In the balance, most individuals who
have osteoporosis are much better taking an osteoporosis medication [11].
2.7. Alternative approach to prevention and treatment of osteoporosis
Considering the possible adverse side effects of HRT and the ever increasing reports on the
side effects of bisphosphonates in the management of postmenopausal osteoporosis, there is
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an increasing demand for complementary and alternative medicine (CAM) for the prevention
and treatment of osteoporosis [56]. CAM is the term for medical practices, services and
products that are not a part of standard care. Some of the approaches include exercise,
acupuncture, diet, herbs rich in polyphenols and nutritional supplements including calcium,
zinc, magnesium boron and other vitamins and minerals. Recent dietary guidelines for the
prevention of chronic diseases have recommended an increase in the consumption of fruits
and vegetables worldwide [57] that are good sources of dietary antioxidants [58]. The beneficial
effects of antioxidants in bone health and osteoporosis are demonstrated epidemiologically
and through clinical intervention. Given that many nutrients have been identified as being
beneficial to bone health [59,60], there is strong scientific support for the potential benefits of
incorporating therapeutic nutritional interventions with contemporary pharmaceutical
treatments [61]. Diet is now recognized as an important life-style factor in the management of
bone health [62]. As will be reviewed in this chapter, our clinical studies on lycopene treatment
and nutritional supplements containing polyphenols and other nutritional components
showed positive results on bone health.
3. Oxidative stress
Oxidative stress is caused by reactive oxygen species (ROS) which are the main by-products
formed in the cells of aerobic organisms that can initiate autocatalytic reactions in such a way
that the target molecules gets converted into free radicals causing a chain of damage [63]. There
is ample evidence to show that oxidative stress induced by ROS increases the rate of bone loss
and is therefore a risk factor for osteoporosis. Epidemiological evidence in humans and studies
in animals indicate that aging and the associated increase in ROS are responsible for bone loss
[64]. As will be reviewed in later sections, oxidative stress is associated with the activity and
function of both the osteoblasts and osteoclasts cells, the two major bone cells involved in the
pathogenesis of osteoporosis.
Oxidative stress results from the weakening of antioxidant defense or an over production of
ROS in the body. ROS contains one or more unpaired electrons, a state that makes them highly
reactive as they seek out another electron to fill their orbital and stabilize their electron balance
[65]. Therefore, ROS are a family of highly reactive, oxygen-containing molecules and free
radicals, including hydroxyl (OH –), superoxide radicals (O2 –), hydrogen peroxide (H2O2),
singlet oxygen, and lipid peroxides [66]. ROS have an extremely short half-life and are difficult
to measure in humans, but it is possible to measure the damage they cause to protein, lipids,
and DNA and the damage is manifested as chronic diseases including osteoporosis [67]. This
can occur by the induction of apoptosis, reduction of cellular proliferation, cell cycle arrest and
modulation of cellular differentiation [68]. The major intracellular sites for the generation of
ROS are via electron transport chains in the mitochondria, endoplasmic reticulum and nuclear
membranes [69]. Oxidative stress may result from normal metabolic activity [70]; during acute
or chronic immune responses [71]; lifestyle factors such as cigarette smoke [72,73], high alcohol
intake [74,75], low antioxidant status [76], nutrition deficiency [74] excessive sports activity
[77], excessive caffeine [78]; and environmental factors such as ultraviolet radiation, chemicals,
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pollution and toxins [79]. ROS production increases with age [80,81] and is associated with
several chronic diseases including osteoporosis.
4. Antioxidants
Under normal physiological conditions, the cells can fight free radical attack or oxidative stress
by promoting antioxidant defenses. A number of endogenous defense mechanisms are present
in the body, including the metal chelating proteins and the endogenous antioxidant enzymes
catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD). [82]. Exoge‐
nous antioxidants come from dietary sources present in fruits and vegetables containing
several phytonutrient antioxidants such as the carotinoids potent antioxidant lipid-soluble
lycopene; the water-soluble antioxidant polyphenols; and vitamins such as C and E [83]. In
cases where the endogenous antioxidants or antioxidants from diet fail to prevent oxidative
damage, the repair antioxidants come into play which include DNA repair enzymes, lipase,
protease and transferase [69]. When antioxidants loses its fight with oxidative stress, diseases
associated with oxidative stress develop, which include cardiovascular disease, cancer,
diabetes, neurological diseases and osteoporosis [84].
The phytochemical antioxidants that are naturally present in plant- and animal-derived foods
include the carotenoids, which are lipid-soluble, to which the potent antioxidant lycopene
belongs and the water-soluble antioxidants such as polyphenols [85]. Figure 1 is a cartoon
depicting the production of oxidative stress from ROS, the damaging effects they exert on
DNA, lipid and protein which subsequently leads to chronic diseases and the protection
afforded by antioxidants.
Figure 1. Oxidative Stress/Antioxidants & Chronic Diseases
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4.1. Lycopene, a carotinoid lipid-soluble antioxidant
Lycopene is a potent antioxidant that is not synthesized in the body. It is a carotenoid acyclic
isomer of ß-carotene, with no vitamin A activity [86]. It is a highly unsaturated, straight-
chained hydrocarbon containing a total of 13 double bonds, of which 11 are conjugated, making
it one of the most potent antioxidants [84,87]. The singlet oxygen-quenching ability of lycopene
is twice that of ß-carotene and 10 times that of α-tocopherol [88]. The chemistry and antioxidant
properties of lycopene have been comprehensively reviewed [87]. Other than from tomatoes
and processed tomato, the dietary lycopene source of 85% of North Americans, lycopene can al‐
so be obtained from watermelon, pink guavas, and pink grapefruit [85]. Lycopene in an all-
trans configuration such as that found in raw tomatoes, is not readily absorbed. Lycopene is
absorbed more efficiently from processed tomato products than from raw tomatoes because it
is converted from the all-trans to the cis-isomeric configuration with heat processing [89,90].
Since lycopene is a lipid-soluble compound that is absorbed via a chylomicron-mediated mech‐
anism [91], the presence of small amounts of lipids further enhance its absorption [92]. The
health benefits of lycopene may be due to its potent antioxidant property, although there is evi‐
dence for other mechanisms such as its effects on gap junction communication [93] and cell cy‐
cling [94]. The reported average daily intake levels of lycopene vary considerably from country
to country, from 0.7 mg per day in Finland to 25 mg per day in Canada. However, a generally ac‐
cepted universal level of daily intake is 2.5 mg. There is no official recommended daily intake of
lycopene, but based on published research, a daily intake of 7 mg is suggested [95].
The role of lycopene in the prevention of human diseases is supported by a number of evidence
[96]. Giovannicci was the first to publish the initial epidemiological observations suggesting
an inverse relationship between the intake of tomatoes and lycopene and the incidence of
prostate cancer [97]. Since then, there have been several epidemiological as well as clinical
intervention studies showing the relationship between lycopene intake and the prevention of
cancers at other sites, as well as coronary heart disease, hypertension, diabetes, macular
degenerative disease, male infertility, and neurodegenerative disease [84]. The role of lycopene
in bone health has so far been based on its potent antioxidant properties, the well known role
of oxidative stress in bone health, and the limited studies on the effects of lycopene in bone
cells in culture (see below) and more recently, the results of epidemiological studies [39,98].
To date our clinical intervention studies at St. Michael’s Hospital on the role of lycopene and
elucidation of its mechanism in lowering the risk for osteoporosis in postmenopausal women
(aged 50 to 60 years) are so far the only studies reported in the literature.
4.2. Polyphenols, the water-soluble antioxidant
Polyphenols are a class of water-soluble molecules naturally found in plants. They are defined
as compounds having molecular masses ranging from 500 to 3000–4000 Da and possessing 12
to 16 phenolic hydroxy groups on five to seven aromatic rings per 1000 Da of relative molecular
mass [99]. It is estimated that there are 10,000 different phytonutrients (phyto, meaning from
plants). To date, over 8000 polyphenols have been identified [100]. Polyphenols can be divided
into 2 main groups: flavonoids and non-flavonoids [101-103]. The health benefits associated
with fruits, vegetables, red wine, tea, and Mediterranean diets are probably linked to the
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polyphenol antioxidants they contain [59,104,105]. The polyphenols of interest in our study
are a mixture of flavonoids such as quercetin, apigenin, kaempferol and luteolin present in the
supplement greens+TM [106]. greens+TM in combination with another supplement, bone
builderTM, were used in our study on osteoblasts cells and in clinical intervention studies on
the prevention of risk of osteoporosis in postmenopausal women. Studies on polyphenols and
bone will be reviewed in later sections.
5. Studies on the damaging effects of oxidative stress and the beneficial
effects of antioxidants
(Studies involving lycopene and polyphenols will be reviewed at a later section)
5.1. Studies on osteoblasts
The evidence being reported on the role of oxidative stress in osteoblasts has increased
exponentially. Up until 2002, only a few studies were reported. Thus, it was reported that
treatment of rat osteosarcoma ROS 17/2.8 cells with tumor necrosis factor-alpha (TNF-a)
suppressed bone sialoprotein (BSP) gene transcription through a tyrosine kinase-dependent
pathway that generates ROS [107]. Osteoblasts can be induced to produce intracellular ROS
[108,109], which can cause a decrease in alkaline phosphatase (ALP) activity that is partially
inhibited by vitamin E and cause cell death [108,109]. The intracellular calcium (Ca++) activity
in osteoblasts is modulated by H2O2 by increasing Ca++ release from the intracellular Ca++
stores [110]. High concentrations of ROS can damage osteoblast cells to prevent normal growth
and development [111] and have been shown to induce osteoblast death [112]. In osteoblasts,
H2O2 has been shown to decrease cell growth, ALP activity, calcification, mineralization and
gene expression of osteogenic markers such as ALP, bone sailoprotein (BSP) and runt-related
transcription factor 2 (Runx2) [113,114]. More recently, Ueno et al induced oxidative stress by
adding 100 microM H2O2 to osteoblasts cultured from rat bone marrow, and showed that this
treatment substantially impaired the proliferation, differentiation, and mineralization and that
addition of the antioxidant N-acetyl cysteine into the culture restored these damages to a near
normal level [115]]. With their study on hydrogen sulphide, Xu et al concluded that hydrogen
sulfide (H2S) protected MC3T3-E1 osteoblastic cells via a MAPK (p38 and ERK1/2)-dependent
mechanism against hydrogen peroxide (H2O2)-induced oxidative injury that cause the
suppression of proliferation and differentiation of the cells [116].
More recently reported inducers of oxidative stress include Arsenic trioxide [117], Cobalt and
Chromium ion [118] and Vanadium Compounds [119].
In vitro studies suggest an important role for antioxidants in abrogating the effects of oxidative
stress on bone. Trolox, a water soluble vitamin E analogue, was shown to enhance ALP activity
in MC3T3-E1 osteoblast-like cells, thus enhancing osteoblast differentiation by decreasing the
generation of ROS [111]. The addition of metallothionein, a metal-chelating preventative anti‐
oxidant, to primary mouse bone marrow stromal cells impaired H2O2-stimulated NfκΒ signal‐
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ling, consequently preventing any inhibition of osteoblast differentiation [114]. Osteoblasts
have been shown to produce antioxidants such as GPx which can protect against the damaging
effects of ROS [120]. In MC3T3-E1 osteoblast-like cells, treatment with H2O2 to induce oxidative
stress was associated with the prolonged up-regulation in gene expression of the transcription
factor nuclear factor E2 p45-related factor 2 (Nrf2), which regulates antioxidant enzymes by as‐
sisting with recognition of the antioxidant-response element [113]. Using xanthine/xanthine
oxidase to generate ROS, Fatokun et al.[120] showed that damage induced by ROS, as evi‐
denced by decreased cell viability, was prevented by CAT in MC3T3-E1 osteoblast-like cells.
This effect is attributed to the ability of CAT to neutralize H2O2 [120]. Newer mechanism of ac‐
tion of ROS is beginning to come to light. It has been shown that increased ROS production di‐
verts the limited pool of β-catenin from TCF/LEF to FOXO-mediated transcription, converting
the beneficial effects of Wnt/β-catenin on bone, eventually leading to decrease osteoblasts num‐
ber and activity and eventually leading to osteoporosis [121-124].
In recent years, the number of antioxidants reported to prevent oxidative stress in osteoblasts
are as follows: Tetrahydrostibene [125,126], Curculigoside [127], Green tea [128], Simvastatin
[129], N-acetylcysteine [115], flavonoids from parsimmon [130], prevastatin [131], Linarin
[132], Panaxnotaginseng saponin [133], crysoeriol from surya cilliata leaves [134], quercetin
[135] Drynaria fortunei [136], cathamus tinctorium flower extract [137], estrogen [138],
diazoxide, atractylodes japonica root extract [139]. and Myrcetin, a naturally occurring
flavonoid [140]. The mechanism of osteblastic defense against oxidative stress was shown to
involve β-Catenin which serves as a cofactor of the forkhead box O (FOXO) transcription
factors [121].
5.2. Studies on osteoclasts
The mechanisms involved in the differentiation of osteoclasts and their ability to resorb bone
is beginning to be unraveled, and evidence shows that ROS may be involved in this process
[141]. Superoxide was detected both at the osteoclast-bone interface and intracellularly using
nitroblue tetrazolium (NBT), which is reduced to purple-colored formazan by ROS, suggesting
the participation of superoxide in bone resorption [142]. Both the H2O2 produced by endothelial
cells [143] intimately associated with osteoclasts and the H2O2 that is produced by osteoclasts
[144] increase osteoclastic activity and bone resorption. H2O2 may also be involved in osteoclast
motility [144], differentiation of osteoclast precursors [145] and the regulation of osteoclast
formation [146]. Osteoclastic superoxide is produced by NADPH oxidase [147]. The degrada‐
tion of collagen and other proteins is caused by highly destructive ROS as a result of the
reaction of H2O2 with tartrate-resistant acid phosphatase (TRAP), found on the surface of
osteoclasts [148]. 1,25-Dihydroxyvitamin D3 had a direct nongenomic effect on the generation
of superoxide anion (O2_), which was inhibited by estrogen [149]. Estrogen has been reported
to have an antioxidant property [150]. Hormones known to stimulate bone resorption, such as
parathyroid hormone (PTH) [151] and 1,25(OH)2D3, have stimulatory effects on ROS produc‐
tion in osteoclasts [149] and hormones known to have inhibitory effects on bone resorption,
such as calcitonin, inhibit ROS production [151].
Topics in Osteoporosis126
Antioxidants also play a role in osteoclast activity. Osteoclasts produce the antioxidant enzyme
SOD in the plasma membrane [152]. ROS production in osteoclasts was inhibited after treating
the cells with antioxidant enzymes such as SOD [142] and catalase [146]. ROS production in
osteoclasts was also inhibited by estrogen [149], the superoxide scavenger deferoxamine
mesylatemanganese complex [153], pyrrolidine dithiocarbamate (PDTC), and N-acetyl
cysteine (NAC) [154].
Other more recent antioxidant shown to affect osteoclasts include polyphenol extracts from
dried plums [155], curcumerin [156], ascorbic acid [157], salvia miltorrhiza [158], coffee
diterpene Kahweol [159], delthametrin [160], to name a few. The use of antioxidants from
natural sources, such as fruits and vegetables, could be another way of inhibiting ROS. The
use of lycopene and polyphenols in this regard is reviewed in a later section.
5.3. Studies of on animal
OVXed rats were treated with Strontium ranelate and at the end of the treatment, oxidative
parameters including malondialdehyde (MDA) level, superoxide dismutase (SOD), gluta‐
thione peroxidase (GSH-Px) and catalase (CAT) activities were determined by biochemical
analysis methods. Their results showed that Sr has preventive effect on oxidative damage in
ovariectomized rats [161]. Yin et al showed that protection against osteoporosis by statins is
linked to a reduction of oxidative stress and restoration of NO formation in aged and ovar‐
iectomized rats [162]. To investigate the anti-osteoporosis effect of Rhizoma Drynariae (RD),
an effectively traditional Chinese medicine and its action mechanism, Liu et al administered
with or without RD extract at a therapeutic dose to a group of rats for 12 weeks and showed
that the anti-osteoporosis effect of RD has been reliably confirmed by the metabonomics
method and that the osteoporosis might be prevented by RD via, among other things, through
intervening antioxidant-oxidation balance in vivo in rats [163]. Treatment of OVXed rats with
Salvia miltiorrhiza ethanol extract significantly ameliorated the decrease in BMD and trabec‐
ular bone mass according to DEXA and trabecular bone architecture analysis of trabecular
bone structural parameters by μ-CT scanning. As well, SM decreased the released TRAP-5b,
an osteoclast activation marker and oxidative stress parameters including MDA and NO
induced by OVX [164]. Oxidative stress (OS) was assessed 100 days postovariectomy by
measuring the activity of several enzymes, including catalase (CAT), superoxide dismutase
(SOD), and glutathione peroxidase, as well as the concentrations of malondialdehyde (MDA),
nitric oxide (NO), and total sulfhydryl groups in plasma and bone homogenates of OVXed rats
treated with or without vitamin C. Their results suggest that ovariectomy may produce
osteoporosis and oxidative stress in females, and vitamin C supplementation may provide
alterations regarding improvement in OS and BMD values [165]. Curcumin was shown to
inhibit OVX-induced bone loss, at least in part by reducing osteoclastogenesis as a result of
increased antioxidant activity and impaired RANKL signaling [166]. In order to investigate
the pathologic significance of oxidative stress in bones, Nojiri et al showed that mice deficient
in cytoplasmic copper/zinc superoxide dismutase exhibited a distinct weakness in bone
stiffness and decreased BMD, aging-like changes in collagen cross-linking, and transcriptional
alterations in the genes associated with osteogenesis. They further demonstrated that intra‐
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cellular oxidative resulted in the decrease in osteoblast number and accompanied by suppres‐
sion of RANKL/M-CSF osteoclastogenic signaling in bone; treatment with an antioxidant,
vitamin C, effectively improved bone fragility and osteoblastic survival [167].
5.4. Epidemiological and clinical studies on osteoporosis
The detrimental effect of oxidative stress and the beneficial role of antioxidant in osteoporosis
have been reviewed [58,83,168,169]. There is now ample evidence to suggest that ROS-induced
oxidative stress is associated with the pathogenesis of osteoporosis. Thus, epidemiological
studies demonstrated the adverse effect on bone of oxidative stress produced during strenuous
exercise [170]; among heavy smokers [171] and that antioxidants including vitamin C, E and
β-carotene may counteract these adverse effects and reduce the risk of osteoporosis [170-173].
A study of severe osteoporotic syndrome in relatively young males showed evidence linking
osteoporosis to an increase in oxidative stress [174]. Maggio et al [175] demonstrated that
women with osteoporosis had markedly decreased plasma antioxidants. A biochemical link
between reduced bone density and increased oxidative stress biomarker 8-iso-prostaglandin
F alpha (8-iso-PGF) has been reported [176,177]. Positive correlation was found between the
severity of osteoporosis and the level of oxidative stress marker lactic acid in 2 men with
mitochondrial deletion (mtDNA) [178].
Evidence points to the fact that Postmenopausal women are more prone to osteoporosis due
to reduction in estrogen, but there is also ample evidence to support the theory that oxidative
stress which accompanies the reduction in estrogen level may be the cause of osteoporosis
[179]. Indeed, estrogen has been shown to have antioxidant properties [150]. Earlier reports
on the association of oxidative stress with osteoporosis were confined mainly to epidemio‐
logical studies. Vitamins C, E, and A, uric acid, the antioxidant enzymes SOD in plasma and
erythrocytes and GPx in plasma were consistently lower in osteoporotic than in control
subjects. An epidemiological study by Hahn et al [180] found that GPx activity was significantly
higher in postmenopausal women with osteopenia than that of postmenopausal women with
a normal BMD, likely as a primary defense against the high levels of H2O2 in osteopenic women
[180]. Osteoporotic women were found to have significantly depressed activities of CAT, GPx
and SOD, compared to those found in healthy control women [177,181,182]. Furthermore,
concentrations of the antioxidant enzymes SOD and CAT have been positively correlated with
BMD which demonstrates a link between antioxidant status and BMD in postmenopausal
women[182]. Surprisingly, a cross sectional analysis in healthy postmenopausal women aged
60-78 years revealed a negative association between 8-OH-dG levels and BMD of the lumbar
spine, total hip, femoral neck, and trochanter and positive association with type I collagen C-
telopeptide (ICTP) levels, showing that oxidative stress is associated with increased bone
resorption and low bone mass even in otherwise healthy women. Medications used to treat
postmenopausal osteoporosis such as HRT and Raloxifene [183] may act in part to decrease
oxidative stress by acting in part as antioxidants. A 3-month course of Raloxifene therapy
significantly decreased the lipid peroxidation and increased the CAT activity in women with
postmenopausal osteoporosis [177,181,182]. Raloxifene treatment for 12 months significantly
decreased protein oxidation in osteoporotic participants compared to matched, non-osteopor‐
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otic controls [183]. Supplementation of ascorbic acid and alpha-tocopherol was found useful
in preventing bone loss linked to oxidative stress in elderly [181].
Postmenopausal women with osteoporosis have been shown to have markedly reduced serum
concentrations of retinol, β-cryptoxanthin, zeaxanthin and α- and β-carotene, compared to
healthy postmenopausal women [175]. Overall carotenoid intake has been found to be
inversely associated with risk of fracture [184]. Sadly, the effect of β-carotene on the risk of
osteoporosis is still controversial. There are studies which suggest that β-carotene has benefi‐
cial effect on bone [98,185,186], while other studies suggest a null or even detrimental effect,
most probably due to its association with vitamin A [187].
In summary, the studies presented above provide evidence of the detrimental effects of
oxidative stress and beneficial effects of antioxidants on the risk of osteoporosis.
6. Studies on lycopene
The direct role of lycopene in osteoblasts and osteoclasts, the cells involved in the pathogenesis
of osteoporosis is now being unraveled. This involvement is further supported by both
epidemiological and clinical intervention with lycopene in postmenopausal women men who
are at risk of osteoporosis.
6.1. In vitro studies of lycopene in osteoblasts
Only few studies on the effects of lycopene in osteoblasts have been reported. This is most
likely because lycopene is not soluble in the culture medium and needed to be solubilized in
organic solvent before it can be added to the cell culture. In our study, we used lyc-o-mato
preparation that is partially dispersed in micelle form in water. When added to the human
osteoblast-like SaOS-2 cells, lycopene had a stimulatory effect on cell proliferation as well as
a stimulatory effect on alkaline phosphatase activity, a marker of osteoblastic differentiation
in more mature cells but, depending on the time of addition, it had an inhibitory or no effect
on younger SaOS-Dex cells. These findings comprised the first report on the effect of lycopene
on human osteoblasts [188]. In another study, the effect of lycopene on MC3T3 cells (the
osteoblastic cells of mice) was contrary to the findings of Kim et al. [188] in that lycopene had
an inhibitory effect on cell proliferation [189]. The discrepancy in the effects of lycopene on
cell proliferation could be a result of species differences, age of the cells when lycopene was
added or experimental conditions. Both studies, however, reported an effect of lycopene on
the differentiation of the cells by stimulating the alkaline phosphatase activity [188,189] and
gene expression of BSP [189]. The lycopene used in our study is the trans-configuration (95%
trans, 5% cis). Subsequently, we studied which configuration of lycopene will prevent the
damaging effect of oxidative stress as well as repair this damage in human osteoblast cultures.
Lycopene with varying content of cis- and trans- configuration (45:55, 28:72 or 5:95 cis:trans
lycopene) were added to cell cultures before and after challenging with H2O2 and the effect on
the generation of ROS and stimulation of mineralized bone nodule were assessed. Our results
demonstrated that the addition of H2O2 resulted in significant increase in generation of ROS
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(p<0.001), which long-term resulted in a decreased number and area of mineralized bone
nodules (both: p<0.001). Pre- and post-treatment with 45:55 or 28:72 cis:trans lycopene resulted
in significantly lower ROS generation (p<0.001) and higher mineralized bone nodule area
(p<0.05), compared to treatment with H2O2 alone, vehicle or 5:95 cis:trans lycopene. These
findings support the hypothesis that the cis isomers of lycopene are capable of preventing and
repairing the damaging effects of H2O2-induced oxidative stress on the formation of mineral‐
ized bone nodules (unpublished observation) [169,190].
6.2. In vitro studies of lycopene in osteoclasts
To date, there have been only 2 studies on the effects of lycopene in osteoclasts [191,192]. Rao
et al. cultured cells from bone marrow prepared from rat femur in 16 well, calcium phosphate-
coated OsteologicTM multi-test slides. Lycopene was added to the cells in the absence or
presence of the resorbing agent parathyroid hormone (PTH) (1-34) and mineral resorption,
TRAP+ multinucleated osteoclast formation, and NBT-staining were measured. Lycopene
inhibited TRAP+ multinucleated cell formation in both vehicle- and PTH-treated cultures. The
cells that were stained with the NBT reduction product formazan were decreased in number
after treatment with lycopene, indicating that lycopene inhibited the formation of ROS-
secreting osteoclasts [192]. The effect of lycopene on osteoclast formation and bone resorption
was also reported by Ishimi et al in murine osteoclasts formed in co-culture with calvarial
osteoblasts [191]. Their results differed from those of Rao et al [192] in that they found that
lycopene inhibited PTH-induced, but not basal, TRAP+ multinucleated cell formation.
Furthermore, they could not demonstrate any effect of lycopene on bone resorption. They also
did not study the effect of lycopene on ROS production.
6.3. Lycopene intervention studies in animals
Other than our intervention studies to be discussed in the next section, most of the intervention
studies with lycopene were carried out in animals. Liang et al investigated the beneficial effect
of lycopene on bone biomarkers in ovariectomized (OVX) rats. Their results showed that
administration of lycopene (20, 30 and 40 mg/kg b.w.) for 8 weeks to OVXed rats significantly
enhanced BMD, concluding that the consumption of lycopene may have the most protective
effect on bone in OVX [193]. Ke et al fed OVXed rats for 3 months with EM-X, an antioxidant
beverage derived from ferment of unpolished rice, sea weeds and papaya with combinations
of microorganisms and contains, among other things, lycopene. Results showed that rats
receiving EM-X for 3 months after sham operation or ovariectomy had increased bone density
of the middle of femur that was statistically significantly different from unreated rats [194].
6.4. Epidemiological studies on lycopene
A systematic review of the experimental studies on Mediterranean diet and disease prevention
was made and analyzed [195]. Although the Mediterrenean diet comprised of many different
food components, it is striking that one of the components is abundance of plant foods
including fruits, vegetables [195]. The two possible active components in its properties to
prevent diseases are lycopene [196] and polypenols [197]. Epidemiological evidence support
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the beneficial effects of tomatoes and tomato products in the prevention of osteoporosis in the
Mediterranean population [104].
The role of lycopene in the prevention of risk for osteoporosis has recently been reviewed [58,
83,168,169]. Maggio et al [175] and Yang et al [198] both demonstrated that serum lycopene
concentrations are lower in women with osteoporosis than in healthy women of the same age.
The antioxidant mechanistic effect of lycopene is demonstrated by Misra et al. who have shown
that HRT has the same antioxidant effects as lycopene in postmenopausal women by demon‐
strating that lipid peroxidation was significantly decreased while GSH significantly increased
by both [199]. Epidemiological studies revealed the relationship between lycopene and BMD
[185,186,200]. A cross-sectional and longitudinal analyses in men and women were carried out
to evaluate the associations between total and individual carotenoid intakes (a-carotene, β-
carotene, β-cryptoxanthin, lycopene, lutein and zeaxanthin) with BMD at the hip, spine, and
radial shaft and the 4-y change in BMD. Their analyses showed significant associations
between lycopene intake and 4-y change in lumbar spine BMD for women [200] protective
associations by total carotenoids against 4-y loss in trochanter BMD in men and in lumbar
spine in women [98]. On the other hand, radial BMD was not correlated with serum lycopene
in postmenopausal Japanese participants, while there was a weak correlation between radial
BMD and β-cryptoxanthin and β-carotene [185]. These discrepancy maybe resolved by further
in-depth study into the effect of lycopene on BMD. On the positive note, lycopene was shown
to contribute to a decrease in the risk of fragility fracture related to osteoporosis.
We carried out a cross-sectional study in which 33 postmenopausal women aged 50–60 years
provided seven-day dietary records and blood samples for analysis of oxidative stress
parameters and bone turnover markers. Our results showed that postmenopausal women who
consumed an average of 7.4 mg of lycopene per day had significantly higher serum lycopene.
Our finding that the estimated dietary lycopene had a significant and direct correlation with
serum lycopene suggests that lycopene from the diet is bioavailable. Our finding that a higher
serum lycopene was associated with a low NTx (p<0.005) and lower protein oxidation (p<0.05).
supports the antioxidative properties of lycopene involvement in its mechanisms of action in
bone [39].
The overrall conclusions from the epidemiological studies support the beneficial role of
lycopene in the prevention of risk for osteoporosis. Further clinical studies described below
support this conclusion.
6.5. Clinical intervention studies on lycopene
Since our laboratory is the only one to this date that reported clinical intervention studies with
lycopene, this section will focus on reviewing our studies on the role of lycopene in the
prevention of risk for osteoporosis in postmenopausal women.
We carried out 4 different clinical studies. In the first study, the objective was to determine the
effects of a lycopene-restricted diet on oxidative stress parameters and bone turnover markers
in postmenopausal women [38]. To avoid the effects of compounding factors with antioxidants,
women who smoked or were on medications which may affect bone metabolism or have anti‐
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oxidant properties were excluded from participating. Twenty-three healthy postmenopausal
women, 50-60 years old, provided blood samples at baseline and after a one-month lycopene-
depletion period. Serum samples were analyzed for carotenoids; the oxidative stress parame‐
ters protein thiols and lipid peroxidation TBARS; the antioxidant enzymes SOD, CAT and GPx,
and the bone turnover markers BAP and NTX. Results revealed that lycopene restriction result‐
ed in significant decrease in serum lycopene, lutein/zeaxanthin and α-/β-carotene as shown in
Table 2, However, the overall percent change in these serum carotenoids was not as high as that
seen for lycopene. Figure 2 demonstrates that all configurations of lycopene (all trans, 5-cis- and
other cis lycopene) were all decreased after lycopene restriction. The antioxidant enzymes CAT
and SOD were significantly depressed (data not shown). These changes were accompanied by a
significant increase in the bone resorption marker NTx [Figure 3].
Carotenoid
Concentration in serum (nM)
Results of paired
t-test1
Average % change
(mean ± SEM)Baseline (mean ±
SEM)
lycopene restricted , (mean
± SEM)
α-carotene 408.4 ± 131.4 334.4 ± 110.6 p<0.05 -13.03 ± 6.88
β-carotene 1443.0 ± 278.9 1035.0 ± 221.7 p<0.0005 -22.84 ± 5.09
β-cryptoxanthin 403.2 ± 58.4 367.6 ± 47.3 p = 0.229 -1.29 ± 8.21
Lycopene 1171.0 ± 111.1 494.9 ± 48.46 p<0.0001 -54.86 ± 3.59a
Lutein/zeaxanthin 516.4 ± 49.57 443.0 ± 47.04 p<0.01 -12.77 ± 5.03
1 Wilcoxon matched pairs test used for these non-normally distributed data sets.
a Average percent change in lycopene was significantly higher than that seen for all the other carotenoids (p<0.0001),
as determined by unpaired t-test or Mann-Whitney test.
Table 2. Change in serum carotenoid concentrations after postmenopausal women were assigned to Lycopene-
restricted diet for a period of 1 month.
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Figure 2. Decrease in all configurations of lycopene (all trans, 5-cis- and other cis lycopene) in the serum of postmeno‐
pausal women after lycopene restriction.
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Figure 3. Increase in the concentrations of the bone resorption marker, NTx, in the serum of postmenopausal women
after lycopene restriction.
To our knowledge, this is the first study on the effects of dietary lycopene restriction on
increasing the risk for osteoporosis in postmenopausal women which proves that lycopene
may be beneficial in reducing this risk. It can be speculated that this significant increase in the
bone resorption marker NTx may lead to a long-term decrease in BMD and increased fracture
risk as was observed by Brown et al [42], and that a longer restriction period may be detrimental
to a group of postmenopausal women who were already at high risk for osteoporosis. It can
also mean that shorter wash-out periods of no lycopene consumption is all that is needed in
clinical trials examining the effects of lycopene on bone health. In addition, lycopene is present
in a select number of foods; therefore not consuming these products as a part of the regular
daily diet may result in negative health consequences to bone health.
In a second study [37], clinical intervention was carried out to investigate directly the effects
of supplementation with lycopene on decreasing the risk for osteoporosis. Sixty postmeno‐
pausal women, 50-60 years old, were recruited for a fully randomized controlled intervention.
Following a one-month washout without lycopene consumption, participants consumed
either (N=15/group): (1) regular tomato juice, (2) lycopene-rich tomato juice, (3) tomato
lycopene capsules or (4) placebo capsules, twice daily for total lycopene intakes of 30, 70, 30
and 0 mg/day, respectively for 4 months. Serum collected was assayed for oxidative stress
parameters and bone turnover markers. Lycopene-supplementation for 4 months significantly
increased serum lycopene compared to placebo (p<0.001). Since the increase in serum lycopene
was similar for all three supplements, the participants were pooled into a “LYCOPENE-
supplemented” and PLACEBO-supplement group for further statistical analyses. LYCO‐
PENE-supplementation for 4 months resulted in significant increase in total antioxidant
capacity as shown in Figure 4, decreased in oxidative stress parameters protein oxidation
[Figure 5] and lipid peroxidation [Figure 6] which correlated to a decrease in NTx [Figure 7]
in the LYCOPENE-supplemented group; all changes were significantly different from the
PLACEBO group. These findings suggest that it did not matter whether lycopene was in the
form of tomato juice or capsule to exert its potent antioxidant properties beneficial in reducing
the risk of osteoporosis in postmenopausal women [37].
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In a third study [169]. Serum lycopene, bone turnover markers and oxidative stress parame‐
ter data were compared between postmenopausal women who were supplemented with ly‐
copene and those who obtained lycopene from both a low and high daily food intake of
lycopene to determine whether the elevated dose obtained through supplementation was
more beneficial in reducing bone turnover markers than intakes typically obtained from the
usual daily diet. Table 3 showed that women supplemented with lycopene had significantly
lower TBARS and marginally significant lower NTx values than participants who obtained a
low intake (or high intake lycopene, data not show) through their usual daily diets. These
differences in NTx and TBARS may be attributed to a significantly higher concentration of
serum 5-cis in lycopene-supplemented participants compared to low or high usual daily in‐
take participants. This suggests that it is the 5-cis isomer, with the most potent antioxidant
capacity which, at higher concentrations, decreases bone turnover markers due to its ability
to provide the greatest protection against oxidative stress. It also appears to show that sup‐
plementation with lycopene may be necessary in spite of the daily intake of lycopene.
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Figure 4. Increase in the serum total antioxidant capacity of postmenopausal women supplemented with LYCOPENE
compared to placebo capsules for 4 months. Values are mean ± SEM. Values compared within supplement group was
determined to be statistically significant using repeated-measures ANOVA (*p<0.05).
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Figure 5. Increase the serum concentration of thiol (meaning decreased protein oxidation) in postmenopausal wom‐
en supplemented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM.
Values compared within supplement group was determined to be statistically significant using repeated-measures
ANOVA (*p<0.001).
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Figure 6. Decrease in the serum concentration of TBARS or lipid peroxidation in postmenopausal women supple‐
mented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM. Values com‐
pared within supplement group was determined to be statistically significant using repeated-measures ANOVA
(*p<0.001).
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Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supple‐
mented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM. Values com‐
pared within supplement group was determined to be statistically significant at 2 and 4 months using repeated-
measures ANOVA (*p<0.01 and **p<0.001).
In a fourth study, we investigated whether the 172T→A or 584A→G polymorphisms of the
paraoxonase 1 (PON 1) modulated the effects of serum lycopene on bone turnover markers,
oxidative stress parameters and antioxidant capacity in women between the ages of 25-70
years. We showed that the PON1 polymorphism modified the association between lycopene
and NTx and BAP (p<0.02 and p<0.05 for interaction). In the combined 172TT and 584G
genotype, high serum lycopene was associated with decreased BAP (p<0.01) and NTx (p<0.05).
Among those with the combined 172A and 584G genotype, however, increased serum
lycopene was associated with increased BAP (p<0.05) and NTx (p<0.05). These findings show
that PON1 polymorphisms modified the association between serum concentrations of
lycopene and oxidative stress parameters and bone turnover markers and may, therefore,
moderate the risk of osteoporosis [201].
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Mean ± SEM
p value1Low usual daily intake
group
(N=48)
Lycopene-supplemented
group
(N=45)
Lycopene intake (mg/day) 2.59 ± 0.32a 43.33 ± 2.84 <0.0001
Serum lycopene (nM)
Total 1094 ± 80.24 2012 ± 88.56 <0.0001
all-trans 539.0 ± 40.07 979.0 ± 48.48 <0.0001
5-cis 342.4 ± 26.13 685.0 ± 30.22 <0.0001
other-cis 212.6 ± 15.96 347.7 ± 17.36 <0.0001
Total antioxidant capacity (mM) 1.65 ± 0.03 1.66 ± 0.05 0.190
Bone turnover markers
NTx (nM BCE) 21.97 ± 1.11 19.19 ± 0.79 0.047
BAP (U/L) 24.42 ± 1.40 23.56 ± 1.02 0.900
Oxidative stress
parameters
Protein thiols
(μM) 454.7 ± 15.37 455.2 ± 15.50 0.982
TBARS (nmol/mL) 9.06 ± 0.35 6.80 ± 0.35 <0.0001
Antioxidant enzymes
CAT (K/g Hb) 81.50 ± 4.13 58.59 ± 2.06 <0.0001
SOD (U/mg Hb) 47.60 ± 2.44 39.22 ± 4.72 0.001
GPx (U/g Hb) 15.44 ± 1.40 32.82 ± 2.85 <0.0001
1 Data that were not normally distributed were compared using the Mann-Whitney test
a The range of lycopene intake for the low usual daily intake group is 0.0-6.07 mg/day.
Table 3. Comparison of lycopene values, oxidative stress parameters and bone turnover markers between women
who were supplemented with lycopene with those who obtained a low lycopene (not shown) intake from their usual
daily diet (unpaired t-test).
A similar investigation was carried out in a fifth study to assesses whether the PON1 172T→A
polymorphism affects the response to dietary intervention with lycopene. We showed that
supplementation in the TT genotype and carriers of the A allele significantly increased serum
lycopene (both: p<0.0001) while decreasing protein oxidation (p<0.005 and p<0.05, respective‐
ly) and lipid peroxidation (p<0.005 and p<0.0005). However, participants with the TT genotype
responded more favourably to lycopene, with corresponding significant increase in total
antioxidant capacity (TAC) (p<0.01) and significant decrease in NTx (p<0.001); this effect was
not significant in carriers of the A allele. Further analyses showed that there was a significant
interaction between PON1 genotype and change in TBARS (p<0.05) suggesting that supple‐
mentation with lycopene resulted in decreased lipid peroxidation, which interacted with the
PON1 genotype to decrease bone resorption markers in postmenopausal women. These
findings provide mechanistic evidence of how intervention with lycopene may act to decrease
lipid peroxidation and thus the risk of osteoporosis in postmenopausal women [169,202].
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6.6. Concluding remark
There is now ample evidence to show that oxidative stress brought about by the accumulation
of ROS in the body is one of the causes of the development of several chronic diseases including
osteoporosis and that antioxidants such as lycopene can counteract this damaging effect. The
evidence includes studies on their role in osteoclastic resorption and osteoblastic bone
formation, animal intervention studies, epidemiological studies and, more recently, clinical
intervention studies. Considering the possible adverse side effects of the conventional therapy
(eg, HRT and bisphosphonates) in the management of postmenopausal osteoporosis, there is
an increasing demand for the use of antioxidants naturally present in foods. The results of
these studies indicate that lycopene maybe useful either as a dietary alternative to drug therapy
or as a complement to the drugs presently used by women at risk for osteoporosis.
7. Studies on polyphenols
Polyphenols have long been known to have a role in the prevention of chronic diseases such
as cardiovascular diseases, cancers, neurodegenerative diseases, diabetes, or osteoporosis.
Only in the last 10 years has there been an increase in the interest on polyphenols and bone
health [203-206]. Horcajada [204] has recently reviewed the anabolic role of phytonutrients
and especially polyphenols in bone while Trzeciakiewicz [205] reviewed the mechanisms of
action of polyphenol in osteoblast function and its interaction with osteoclasts. The beneficial
effects of green tea polyphenols has been reviewed [207,208].
Currently, most of the research on polyphenols and their effects have emerged from in vitro
and in vivo animal studies with only a few clinical studies available. In our recent review, we
have included tables listing all the studies on polyphenols in vitro bone cell culture and the
epidemiologic studies on the protective effects of polyphenol consumption against osteopo‐
rosis [209] and only a few studies will be reviewed here.
7.1. In vitro studies on polyphenols in bone cells
The most commonly studied polyphenol abundant in green tea is epigallocatechin-3-Gallate
(EGCG). We have shown that epigallocathechin-3-gallate (EGCG) increased the formation of
mineralized bone nodules by human osteoblast-like cells [210]. EGCG has been shown to
inhibit the expression of matrix metalloproteinase 9 (MMP-9) and the formation of osteoclasts
[211]. H2O2-induced alterations of osteoblast viability and reduction in alkaline phosphatase
activity were prevented by pre-incubating the osteoblasts with green tea polyphenol [212].
Green tea was shown to protect human osteoblasts from cigarette smoke-induced injury [128].
EGCG was shown to inhibit thyroid hormone-stimulated osteocalcin synthesis in osteoblasts
[213], suppressed the differentiation of murine osteoblastic MC3T3-E1 cells [214], inhibit rat
osteoclast formation and differentiation [215] and induces apoptosis via caspase activation in
osteoclasts differentiated from RAW 264.7 cells [216]. Horcajada suggested that most studies
investigating the effects of polyphenols on osteoblast cells have reported involvement of
complex networks of anabolic signaling pathways such as BMPs or estrogen receptor mediated
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pathways [204]. Trzeciakiewicz describing a more detailed mechanisms, suggested that
polyphenols modulate the expression of transcription factors in osteoblasts such as runt-
related transcription factor-2 (Runx2) and Osterix, NFkappaB and activator protein-1 (AP-1)
[205]. In agreement with Hocajada (2012), Trzeciakiewicz (2009) stated in his review that
polyphenol may act on cellular signaling such as mitogen-activated protein kinase (MAPK),
bone morphogenetic protein (BMP), oestrogen receptor and osteoprotegerin/receptor activator
of NF-kappaB ligand (OPG/RANKL) and thus may affect osteoblast functions. The two
reviews complement each other and paint a better understanding of the mechanisms of action
of polyphenols in bone cells, with the warning that it is also important to take into account the
possible interaction of these compounds on osteoblasts metabolism.
Other polyphenols/sources of polyphenols which were found to have beneficial effects on bone
cells include the dried plum polyphenols found to attenuate the detrimental effects of
TNFalpha on osteoblast function coincident with up-regulation of Runx2, Osterix and IGF-I
and increasing lysyl oxidase expression, and at the same time attenuate osteoclastogenesis
signalling [217]; black tea polyphenol which affects the MMP activity and osteoclast formation
and differentiation in vitro [215]; phenolic leaf extract of Heimia myrtifolia (Lythraceae) found
to stimulate mineralization of SaOS-2 osteosarcoma cells) [218]; Oleuropein which enhances
osteoblastogenesis and inhibits adipogenesis and the effects on differentiation in stem cells
derived from bone marrow [219] and the polyphenol component of red wine resveratrol which
promotes osteogenic differentiation and protects against dexamethasone damage in murine-
induced pluripotent stem cells [220] and facilitates in vitro mineralization and in vivo bone
regeneration [221]. A number of animal studies have been reported and this was reviewed by
Rao et al [209].
Other good sources of polyphenols that are frequently studied are extracts containing
combinations of polyphenols. One such source is the nutritional supplement greens+TM, a blend
of several herbal and botanical products containing a substantial amount of polyphenols
including quercetin, apigenin and luteolin [106] which act as antioxidants and therefore should
be able to counteract oxidative stress. Our laboratory has shown that the polyphenolic extracts
from greens+TM have stimulatory effect on mineralized bone nodule formation in human
osteoblast cells in a dose- and time- dependent manner and is more effective than epicatechin
(EC) as shown in Figure 8 [222]. We have further shown that this stimulatory effect is accom‐
panied by decreases in the reactive oxygen species H2O2 shown in Figure 9 [223], thus proving
that greens+TM is able to counteract oxidative stress in human osteoblastic cells and may
therefore be a good candidate as a nutritional supplement to prevent the risk of osteoporosis.
Two additional nutritional supplements have since been formulated which may prove to be
good for bone health. These are the bone builderTM and the greens+bone builderTM ; the latter
is the original greens+TM product that has been supplemented with the bone builderTM formula
containing several compounds including vitamins, minerals, and antioxidants. These various
components have been separately shown to have some beneficial effect on bone [224]. Using
the human osteoblast SaOS-2 cells, we showed that similarly to the greens+TM, the water-
soluble bone-builderTM extract had a significant dose-dependent stimulatory effect on bone
nodules formation (Figure 10) [225]. Figure 11 shows that when the two supplements, greens
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+TM and bone builderTM, were tested as combination, the effects were six times more effective
than either one alone in stimulating bone formation in osteoblast culture [226].
Figure 8. Effect of continuous addition of greens+TM extract on the number of SaOS-2 cells cultured in the presence of
EC, or varying dilutions of greens+TM at an early time points and number of nodules analyzed at the indicated time
points. An asterix, *, on a bar indicates statistical significance (p <.05) between a treatment and the control.
Figure 9. Dose-dependent inhibitory effects of phenolic extracts of greens+TM on intracellular ROS levels stimulated by
20 uM H2O2 in SaOS-2 cells. Data are mean ± SEM of 6 replicates. *p = < 0.05.
Oxidative Stress and Antioxidants in the Risk of Osteoporosis — Role of the Antioxidants Lycopene and Polyphenols
http://dx.doi.org/10.5772/54703
139
0.0 0.1 0.3 0.5 0.7 0.8 0.9 1.0
0
500
1000
1500
2000
day 17
day 20


 

#
#



# #
concentration of bonebuilder (mg/ml)
ar
ea
 
of
 
m
in
er
al
ize
d 
bo
ne
 
n
od
ul
es
(ar
bi
tra
ry
 
un
it 
in
 
pi
xe
ls/
w
el
l)
Figure 10. Time and Dose-dependent Effects of bone builderTM on mineralized bone nodule area in SaOS-2 cells. indi‐
cates significant difference from vehicle: p<0.0001; p<0.0005; p<0.005, #, p<0.01 and ##, p< 0.05. There is a signifi‐
cant dose-dependent effect both at day 17 and day 20, according to One-way ANOVA; p<0.0001.
Figure 11. Dose dependent effect of greens + (g+) with and without 0.5 mg/ml of bone builder (bb) on the area of
mineralized bone nodules in osteoblasts SaOS-2 Cells. Significant differences were found compared to respective con‐
trols. g+bb was more effective than either g+ or bb alone.
7.2. Clinical intervention studies of polyphenol
We have recently reviewed earlier clinical studies on polyphenols and osteoporosis [209]. Only
the more recent reports, as well as our own clinical studies will be reviewed here. Shen et al
[227] have extended their studies in osteopenic women and showed that dietary supplement
in the form of green tea combined with tai-chi, a mind-body exercise, can alleviating bone loss
in osteopenic women. The effect of catechin was studied in perimenopausal Scottish women
Topics in Osteoporosis140
and it was found that catechin was negatively associated with bone-resorption markers,
association between energy-adjusted total flavonoid intakes and BMD at the femoreal neck
and lumbar spine while annual percent change in BMD was associated with intakes of
procyanidins and catechins [228].
Other than these clinical studies in the last two years, there has not been not been anymore
reported clinical studies on polyphenols in human subjects except our studies.
Our  results  on the  in  vitro  effects  of  greens+TM,  bone builderTM  and greens+bone build‐
erTM on bone formation in osteoblasts encouraged us formed the rationale for our clinical
studies to test whether these products can prevent the risk of osteoporosis in postmeno‐
pausal women. We chose to study the greens+bone builderTM since of the three products,
it  gave the greatest  stimulatory effect  on bone formation,  being six times more effective
than the  other  two.  The first  randomized cross-sectional  clinical  intervention study was
carried out  to  test  whether  a  daily  supplementation with  greens+  bone builderTM may
be important in reducing oxidative damage in postmenopausal women at risk for osteo‐
porosis.  [40].  Forty-seven postmenopausal  women,  50-60  years  old  were  randomized to
either Treatment group consuming 1 scoop (equivalent to ¼ cup) daily of greens+ bone
builderTM  (N=23) or Placebo (N=24) group for a period of 8 weeks.  Blood samples were
collected at 0, 4 and 8 weeks of supplementation, processed and assayed for serum total
antioxidant capacity (TAC), lipid peroxidation and protein oxidation as markers of oxida‐
tive stress. Results revealed that there was an increase in total antioxidant capacity (Fig‐
ure 12, as well as a decrease in both protein oxidation (Figure 13) and lipid peroxidation
(Figure 14) over a 4 and 8-weeks of intervention with greens+ bone builderTM  compared
to placebo. This suggests that the nutritional supplement may have a beneficial effect on
bone health by counteracting the effects of oxidative stress [40].
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Figure 12. Change relative to baseline in serum concentrations of trolox, a measure of total antioxidant capacity, in
greens+bone builderTM-treated postmenopausal women was significantly increased after 4 and 8 weeks while that in
the placebo-treated control was marginally decreased. Treated values were also higher than the placebo [unpaired t-
test (*p<0.01, **p<0.0001)]. Values are mean ± SEM.
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Figure 13. Change relative to baseline in serum concentrations of thiol in greens+bone builder-treated postmeno‐
pausal women was significantly increased after 4 and 8 weeks (meaning decreased protein oxidation) while that in
the placebo-treated control was unchanged; treated values were also higher than the placebo. Mann-Whitney test
(*p<0.05, **p<0.001). Values are mean ± SEM.
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Figure 14. Change relative to baseline in serum concentrations of TBARS in greens+bone builderTM-treated postmeno‐
pausal women was significantly decreased after 4 and 8 weeks (meaning decreased lipid peroxidation) while that in
the placebo-treated control was unchanged; treated values were also lower than the placebo. Mann-Whitney test
(*p<0.05, **p<0.001). Values are mean ± SEM.
In order to test whether the antioxidant properties of greens+bone builderTM can prevent the
risk of osteoporosis in postmenopausal women, we also measured the serum bone turnover
markers, C-terminal telopeptide of type I collagen (CTX) as indicator of bone resorption, and
procollagen type I N-terminal propeptide (PINP) as indicator of bone formation, in addition
to the serum antioxidant capacity, and the oxidative stress parameters lipid peroxidation,
protein oxidation. As shown in Figure 15, statistical analysis showed that at 8 weeks, the greens
+bone builderTM supplement group significantly decreased the bone resorption marker CTX,
while the Placebo group showed no significant changes. The supplement group was also
significantly different from that of the Placebo group in all parameters measured. This decrease
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in CTX correlated to the increase in their serum total antioxidant capacity [Figure 12] and
decreases in oxidative parameters protein oxidation [Figure 13] lipid peroxidation [Figure
14]. These results suggest that a daily supplementation with polyphenols and micronutrients
may be important in reducing oxidative damage by reducing bone resorption, thereby
reducing the risk of osteoporosis in postmenopausal women [41].
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Figure 15. Change relative to baseline in serum concentrations of CTX in greens+bone builderTM-treated postmeno‐
pausal women was significantly decreased after 8 weeks (meaning decreased bone resorption marker) compared to
that of the placebo-treated control (a paired t-test (*p<0.05).. Values are mean ± SEM.
7.3. Concluding remarks
Studies reported in the literature on the role of polyphenols in bone health have explod‐
ed in  the  last  10  years,  but  most  of  the  reports  involved in  vitro  studies  in  osteoclasts
and  osteoblasts,  animal  studies  and  epidemiologicai  studies.  There  is  little  doubt  from
the excellent studies reported that oxidative stress is one of the primary culprits responsi‐
ble for the pathogenesis of osteoporosis via its role in osteoclastic resoption and the detri‐
mental  effects  on  the  bone-forming  osteoblasts.  To  date,  only  four  clinical  intervention
studies  have  been  reported,  including ours.  It  is  easy  to  see  why it  is  very  difficult  to
evaluate the role of polyphenols since, as we learned from this review, there are at least
8,000 different polyphenols identified to date, and each one probably having different ef‐
fects  on  humans.  Additionally,  polyphenols  are  present  in  food with  other  constituents
that may also be beneficial to bone health. In our clinical study, we combined the effects
of  a  combination  of  polyphenols  present  in  the  nutritional  supplement  from  greens+TM
with  the  nutritional  components  present  in  bone  builderTM  such  as  minerals,  vitamins
and other nutrients.  It  is  possible  that  the effects  of  greens+bone buildertm  in  increasing
total  antioxidant capacity,  decreasing the oxidative stress markers protein oxidation and
lipid peroxidation which correlated to the decrease in bone turnover marker for bone re‐
sorption is a result of the combined effects of the different polyphenols it contained with
those of the other nutritional components present in the bone builderTM.  It  remained for
future studies to zero in on specific component that is responsible for its beneficial effect.
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8. General summary and conclusion
In conclusion, we showed that oxidative stress due to ROS that are shown to cause the
development of osteoporosis may be prevented by supplementation with the antioxidants
lycopene and polyphenols. Results of in vitro studies in osteoblasts and osteoclasts, animal
intervention studies, epidemiological studies and clinical intervention studies on lycopene and
polyphenols are evidence for their potential use as alternative or complementary agent with
other established drugs approved for the prevention or treatment of osteoporosis in postme‐
nopausal women.
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